Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Amplia's Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Investor Information
Home
>
Investor Information
>
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Coverage
31-Aug-2022
Amplia Therapeutics receives $1.8 million R&D refund for cancer inhibitor studies
3-Aug-2022
Amplia Therapeutics achieves critical clinical milestone for lead cancer therapy
3-Oct-2021
Amplia Therapeutics says Garvan paper has increased its confidence in upcoming Phase 2 trial
28-Sep-2021
Amplia Therapeutics and Patrys outline unique cancer drugs at Proactive Lifesciences Webinar
26-Jul-2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
26-Jul-2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
21-Jul-2021
Amplia Therapeutics returns successful phase one trial results
19-Jul-2021
Garvan's June Seminar: The Power of Personalised Medicine
30-Jun-2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
28-Jun-2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Click here for archives
